Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits and COVID-19 testing-related sales of around $2B. FY23 revenue consensus $39.51B.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott Delivers Better-than-Expected Q4 Earnings
- Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
- Notable companies reporting before tomorrow’s open
- Abbott price target raised to $110 from $105 at Mizuho
- Pharma Industry Could Benefit from Rise in Medicine Spending
